NCT03589898View on ClinicalTrials.gov

Study of Neuroimaging Biomarkers of Social Cognition Deficits in Adolescents (Age 13-17) With Autism Spectrum Disorder and Effects of Gabapentin

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 14, 2017

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions
Autism Spectrum Disorder
Interventions
DRUG

Gabapentin

Single dose of gabapentin 900 mg

Trial Locations (1)

01655

University of Massachusetts Medical School, Worcester

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

Johns Hopkins University

OTHER

lead

University of Massachusetts, Worcester

OTHER

NCT03589898 - Study of Neuroimaging Biomarkers of Social Cognition Deficits in Adolescents (Age 13-17) With Autism Spectrum Disorder and Effects of Gabapentin | Biotech Hunter | Biotech Hunter